At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 65 enrolled
Drug / intervention
Vascana (0.9% nitroglycerin cream) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-blinded Crossover Study of Topical Formulation of Nitroglycerine, Vascana®, Versus Matching Vehicle in the Subjective and Physiologic Responses to Controlled Cold Challenge in Subjects With Raynaud's Phenomenon (RP) Secondary to Connective Tissue Disease
In Brief
A Phase 2 clinical trial evaluating Vascana (0.9% nitroglycerin cream) and Vehicle Cream (placebo) for Raynaud's Phenomenon Secondary to Connective Tissue Disease. Completed, enrolled 65 participants across 1 site.
Detailed Summary
The purpose of this study is to determine the ability of Vascana (0.9% nitroglycerin topical cream) to treat and prevent the symptoms experienced by subject's with Raynaud's Phenomenon. The symptoms of this disease include pain, tingling, and numbness in the fingers of the affected hand or hands.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedFeb 2016
Enrollment StartJun 2016
Primary CompletionDec 2016
TodayJul 2026
First PostedFeb 23, 2016
Enrollment StartJun 1, 2016
Primary CompletionDec 1, 2016
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 10.4 years ago
Interventions
Vascana (0.9% nitroglycerin cream)drug
Study drug administered topically
Vehicle Cream (placebo)drug
Vehicle administered topically